醫療科技評估 Health Technology Assessment
連結醫藥科技研究與政策決定的橋樑 is the systematic evaluation of properties, effects, and/or impacts of health technology

產業輔導

6. 國外已經做過HTA或經濟評估的產品,國內是否還要再做呢? If the assessment reports from the UK, Canada and Australia are used as reference, do products that have undergone HTA or economic assessment...

發佈日期:
點閱次數:492

       這個問題的考量點在於國內的醫療費用結構,以及已經列入健保給付的藥品品項,可能與其他國家的狀況不同,因此在考量新申請藥品及其他已獲給付的藥品,在台灣使用時相對的成本效益時,可能跟國外的狀況不完全一樣。再來如果該申請列入給付的新藥品若有種族上療效或安全性的差異性時,新藥在國內使用時與其他類似治療目的藥品比較的臨床效益與經濟議題,則必需再作另外考量。
       另外,還需要考慮到國內衛生福利部核可的適應症,以及臨床流病資料反映出來的適用病人數狀況,評估該申請藥品列入給付之後可能造成健保財務的衝擊,這些資料是沒有辦法從國外的評估報告當中得到的。還有就是整理翻譯後的資料,還是需要有人花時間確認資料的客觀性與完整性的,因此廣義來說,我們在台灣還是有不同的程度需求,要進行藥品納入健保給付的科技評估。國外的評估報告可以提供我們評估重點的參考,確實可以節省不少從頭查詢整理所有相關原始資料的時間。

 

The consideration regarding this issue is that the provided service and expense of local healthcare structure may be different from that of other countries. Thus, the cost-effectiveness comparison of the proposed new drugs to other NHI-listed drugs in Taiwan scenario might be completely different from that of other countries.In addition, if there are ethnic differences in efficacy and safety for new drugs submitted for NHI listing, it will be more reasonable to perform HTA based on local usage condition.
Furthermore, the Ministry of Health and Welfare-approved indications, local disease epidemiological data and the likely impact on the NHI's finances must be taken into considered. Such data cannot be obtained from assessment reports from other countries. Another issue is that the objectivity and integrity of the translated data need to be confirmed. In conclusion, there is a different level of actual demand in Taiwan for performing technology assessments on new drugs NHI listing. However, assessment results from other countries are important references to significantly reduce the time spent on searching and compiling relevant raw data from scratch.